A laser catheter for treating cerebrovascular diseases and a cerebrovascular disease treatment system

Abstract

A laser catheter for treating cerebrovascular diseases includes a catheter body and a core. The core is used for laser transmission and imaging. The catheter body is encased within the core, and the outer diameter of the catheter body is D, which must satisfy 10µm ≤ D ≤ 500µm. The core of the laser catheter simultaneously has laser transmission and imaging functions. Utilizing the imaging function of the core, an imaging device confirms the position of the laser catheter in the cerebral blood vessels and guides the movement of the laser catheter, ensuring the tip of the laser catheter accurately reaches the cerebrovascular lesion. Then, using the laser transmission function of the core, in conjunction with an external laser emitting device, the therapeutically effective laser is transmitted to the cerebrovascular lesion. The laser is used to treat the cerebrovascular lesion, and the treatment effect is confirmed to generate feedback, determining the treatment endpoint. This achieves the therapeutic effect for cerebrovascular diseases without the need for additional implantable high-value medical consumables.

Description

Technical Field

[0001] This application relates to the field of medical device technology, and in particular to a laser catheter and a cerebrovascular disease treatment system. Background Technology

[0002] Cerebrovascular diseases and systemic peripheral vascular diseases have a high incidence rate in the population, affecting a large number of people. The causes are generally abnormal degeneration and proliferation within the blood vessels or impaired blood flow, typically manifesting as hemorrhagic cerebrovascular diseases such as arteriovenous aneurysms and arteriovenous fistulas, or ischemic cerebrovascular diseases such as ischemic stroke and vascular occlusion. Furthermore, the cerebral vascular structure itself is intricate. The brain's activity and metabolism depend on the network of intracranial vessels for blood and nutrient supply. Compared to the cardiovascular vessels, which have diameters of several hundred micrometers or even up to 1 cm, cerebral vessels are much narrower and more tortuous, with diameters generally ranging from 10 to 500 micrometers. If lesions such as arteriovenous fistulas or arteriovenous malformations occur, the complexity is even greater.

[0003] Traditional treatments for the aforementioned cerebrovascular diseases involve surgical procedures such as fenestration, which are highly invasive. To minimize this damage, current technology utilizes neurointerventional techniques, often considered the "ceiling" of vascular interventional therapies. This involves guiding an X-ray-detectable catheter / guidewire through a blood vessel to the lesion, while real-time or intermittent imaging confirms its position. However, the catheter / guidewire itself has no therapeutic effect; it cannot treat the lesion or improve the condition. It merely serves as a carrier or channel to guide other therapeutic medical devices, such as balloons or coils, to the lesion. Summary of the Invention

[0004] Therefore, it is necessary to provide a laser catheter and cerebrovascular disease treatment system that is simple to operate, low in cost, and has good therapeutic effect.

[0005] A laser catheter for the treatment of cerebrovascular diseases, the laser catheter comprising a catheter body and a fiber core, the fiber core being used for laser transmission and capable of imaging, the catheter body being disposed outside the fiber core, the outer diameter of the catheter body being D, wherein D needs to satisfy 10um≤D≤500um.

[0006] The beneficial effects of adopting this solution are:

[0007] Compared to existing technologies, the laser catheter of this application has both laser transmission and imaging functions in its fiber core. Utilizing the imaging function of the fiber core, the position of the laser catheter in the cerebral blood vessels is confirmed by an imaging device, which also guides the movement of the laser catheter, ensuring the tip of the laser catheter is precisely positioned at the cerebral vascular lesion. Then, using the laser transmission function of the fiber core, in conjunction with an external laser emitting device, the therapeutically effective laser is transmitted to the cerebral vascular lesion. The laser is used to treat the cerebral vascular lesion, and the treatment effect is confirmed, feedback is generated, and the treatment endpoint is determined. This eliminates the need for additional implantable high-value medical consumables, achieving the therapeutic effect for cerebrovascular diseases, simplifying operation, saving material costs, and enhancing treatment efficacy.

[0008] The laser catheter in this application is mainly used for cerebrovascular diseases. Since the inner diameter of cerebral blood vessels is small, in order for the laser catheter to move smoothly in the cerebral blood vessels, the outer diameter of the laser catheter needs to be smaller than the inner diameter of the cerebral blood vessels, so D≤500um is controlled. However, for capillaries in cerebral blood vessels with an inner diameter of less than 10um, it generally does not cause major clinical problems. Moreover, the smaller the fiber core, the greater the difficulty of the processing technology and the more difficult it is to achieve mass production. Therefore, taking into account both practical use and processing technology, D≥10um is controlled in this application.

[0009] In one embodiment, the catheter body includes a cladding that covers the fiber core. The refractive index of the fiber core is greater than that of the cladding, so that the laser undergoes total internal reflection between the fiber core and the cladding, reducing transmission loss and ensuring the light guide efficiency of the laser, thereby ensuring the treatment effect.

[0010] In one embodiment, the cladding is a gel polymer cladding. The cladding uses a gel polymer material. Gel polymers have a low refractive index, which easily meets the requirement of being less than the refractive index of the fiber core. In addition, gel polymers can conduct laser light without being transparent, and have heat insulation function, low heat energy consumption, and low loss and leakage during conduction. At the same time, gel polymers have good elasticity and flexibility, so that the cladding can move flexibly in the tortuous cerebral blood vessels, ensuring the laser transmission effect without causing damage to the cerebral blood vessels.

[0011] In one embodiment, the fiber core is a silicone rubber core containing rare earth metals. Silicone rubber has a high refractive index, which easily meets the requirement of being greater than the cladding refractive index. In addition, silicone rubber has good high-temperature resistance and can maintain good elasticity and flexibility at high temperatures, so that the fiber core can move flexibly in tortuous cerebral blood vessels. The addition of rare earth metals to the silicone rubber allows the fiber core to be visualized under digital subtraction angiography (DSA) or other X-ray imaging devices without affecting the light guiding of the fiber core.

[0012] In one embodiment, the rare earth metal includes one or more of yttrium, neodymium, erbium, and ytterbium. These rare earth metals are inexpensive and readily available, reducing the material cost and production difficulty of the fiber core.

[0013] In one embodiment, the catheter body further includes a protective layer disposed outside the sheath to protect the sheath and the fiber core from damage.

[0014] In one embodiment, the catheter body further includes a lubricating layer disposed outside the sheath. The lubricating layer allows the laser catheter to move flexibly within the blood vessel without damaging the structure of the cerebral blood vessels themselves, ensuring excellent biocompatibility of the laser catheter.

[0015] In one embodiment, the wavelength of the laser transmitted in the fiber core is 500-1100 nm and the intensity is 0.1 W-30 W. The laser can thermally coagulate photochemical agents in cerebral blood vessels at the cerebral vascular lesion tissue.

[0016] For hemorrhagic cerebrovascular diseases, a combination of local laser irradiation and photochemical agent injection is used. By selecting appropriate photochemical agents and lasers with suitable wavelengths and intensities, the photochemical agents produce a photochemical reaction and thermal coagulation at the lesion site under laser irradiation, which plays a role in local blood coagulation and blockage, thereby cutting off the blood supply to the lesion site and achieving an embolization effect.

[0017] In one embodiment, the wavelength of the laser transmitted in the fiber core is 800-1500 nm, and the laser is capable of ablating cerebrovascular lesions.

[0018] For ischemic cerebrovascular diseases such as ischemic stroke, vascular occlusion, and vascular stenosis, a suitable laser is selected to irradiate the diseased tissue. The high energy of the laser is used to ablate and decompose the obstructing substances in the blood vessels, thereby restoring normal blood vessel diameter and blood perfusion.

[0019] Another technical solution disclosed in this invention is as follows:

[0020] A cerebrovascular disease treatment system includes an imaging device and a laser treatment device. The laser treatment device includes a main unit and a laser conduit for treating cerebrovascular diseases as described in any of the above technical solutions. The laser conduit is connected to the main unit. The imaging device monitors the patient's brain condition in real time and guides the laser conduit to move in the cerebral blood vessels toward the cerebrovascular lesion. The main unit controls the output of the laser when the end of the laser conduit reaches the cerebrovascular lesion.

[0021] In one embodiment, the imaging device displays the condition of the cerebral blood vessels and guides the laser catheter to move within the cerebral blood vessels;

[0022] When the laser catheter tip reaches the cerebrovascular lesion tissue, the host controls the output of the laser to irradiate the cerebrovascular lesion tissue.

[0023] In one embodiment, the host computer controls the output of the laser to irradiate the cerebrovascular lesion tissue, including:

[0024] The wavelength of the laser output is controlled by the host computer, which ablates cerebrovascular lesions under laser irradiation.

[0025] Alternatively, a photochemical reagent can be injected into the cerebrovascular lesion tissue, and the wavelength of the output laser can be controlled by the host machine. The laser irradiation causes the photochemical reagent to thermally coagulate and embolize at the cerebrovascular lesion tissue. Attached Figure Description

[0026] To more clearly illustrate the technical solutions in the embodiments of this application or the conventional technology, the drawings used in the description of the embodiments or the conventional technology will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0027] Figure 1 This is a schematic diagram of cerebrovascular disease (arteriovenous malformation).

[0028] Figure 2 This is an angiographic image of cerebrovascular disease (arteriovenous malformation) under digital subtraction angiography (DSA).

[0029] Figure 3 This is a schematic diagram of the cardiovascular system.

[0030] Figure 4 This is an angiographic image of the cardiovascular system under digital subtraction angiography (DSA).

[0031] Figure 5 This is a schematic diagram showing the laser catheter for treating cerebrovascular diseases reaching the cerebrovascular lesion tissue provided in this application.

[0032] Figure 6 The radial cross-sectional view of the laser catheter for the treatment of cerebrovascular diseases provided in this application.

[0033] Figure 7 The application provides an axial radial sectional view of a laser catheter for the treatment of cerebrovascular diseases.

[0034] Figure 8 This application provides a schematic diagram of a cerebrovascular disease treatment system.

[0035] Figure 9The application provides a flowchart of the steps involved in treating ischemic cerebrovascular disease using a cerebrovascular disease treatment system.

[0036] Figure 10 The application provides a flowchart of the steps involved in treating hemorrhagic cerebrovascular disease using a cerebrovascular disease treatment system.

[0037] Figure label:

[0038] 100. Main unit; 200. Laser catheter; 210. Fiber core; 220. Cladding; 230. Protective layer; 240. End; 250. Lubricating layer; 300. C-arm angiography machine; 400. Suspended display screen; 500. Diseased tissue; 600. Cerebral blood vessels. Detailed Implementation

[0039] To make the above-mentioned objectives, features, and advantages of this application more apparent and understandable, the specific embodiments of this application are described in detail below with reference to the accompanying drawings. Many specific details are set forth in the following description to provide a thorough understanding of this application. However, this application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar modifications without departing from the spirit of this application. Therefore, this application is not limited to the specific embodiments disclosed below.

[0040] It should be noted that when a component is referred to as being "fixed to" or "set on" another component, it can be directly on the other component or there may be an intermediate component. When a component is considered to be "connected to" another component, it can be directly connected to the other component or there may be an intermediate component present. The terms "vertical," "horizontal," "upper," "lower," "left," "right," and similar expressions used in this application's specification are for illustrative purposes only and do not represent the only possible implementation.

[0041] Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one of that feature. In the description of this application, "multiple" means at least two, such as two, three, etc., unless otherwise explicitly specified.

[0042] In this application, unless otherwise expressly specified and limited, "above" or "below" the second feature can mean that the first feature is in direct contact with the second feature, or that the first feature and the second feature are in indirect contact through an intermediate medium. Furthermore, "above," "over," and "on top" the second feature can mean that the first feature is directly above or diagonally above the second feature, or simply indicates that the first feature is at a higher horizontal level than the second feature. "Below," "below," and "under" the second feature can mean that the first feature is directly below or diagonally below the second feature, or simply indicates that the first feature is at a lower horizontal level than the second feature.

[0043] Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used in this application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. The term "and / or" as used in this application includes any and all combinations of one or more of the associated listed items.

[0044] The laser catheter 200 for treating cerebrovascular diseases and the cerebrovascular disease treatment system of the present invention will be described in further detail below with reference to the accompanying drawings and specific embodiments:

[0045] Please see Figure 8 This application provides a cerebrovascular disease treatment system for the treatment of hemorrhagic or ischemic cerebrovascular diseases. The system includes an imaging device and a laser treatment device. The laser treatment device includes a main unit 100 and a laser conduit 200 for the treatment of cerebrovascular diseases, and the laser conduit 200 is connected to the main unit 100.

[0046] The imaging device is used to display and monitor the patient's brain condition in real time, and guide the laser catheter 200 to move in the cerebral blood vessel 600 to the cerebral vascular lesion tissue 500. Specifically, it includes a C-arm angiography machine 300 and a suspended display screen 400. The host 100 controls the laser output when the laser catheter tip 240 reaches the cerebral vascular lesion tissue 500, so as to irradiate the cerebral vascular lesion tissue 500.

[0047] like Figure 6 and Figure 7 As shown, the laser catheter 200 for the treatment of cerebrovascular diseases of this application includes a catheter body and a fiber core 210. The fiber core 210 is used for laser transmission and can be visualized. The catheter body is wrapped around the fiber core 210. The outer diameter of the catheter body is D, and D needs to satisfy 10um≤D≤500um.

[0048] In this embodiment, the fiber core 210 of the laser catheter 200 has both laser transmission and imaging functions. Utilizing the imaging function of the fiber core 210, the position of the laser catheter 200 within the cerebral blood vessel 600 is confirmed by an imaging device, which also guides the movement of the laser catheter 200, ensuring its tip precisely reaches the cerebral vascular lesion 500. Then, using the laser transmission function of the fiber core 210, in conjunction with an external laser emitting device, a therapeutically effective laser is transmitted to the cerebral vascular lesion 500. The laser is used to treat the cerebral vascular lesion 500, and the treatment effect is confirmed, feedback is generated, and the treatment endpoint is determined. This achieves the therapeutic effect for cerebrovascular diseases without the need for additional implantable high-value medical consumables, simplifying operation, saving material costs, and enhancing treatment efficacy.

[0049] Reference Figures 1-4 visible, Figure 1 and Figure 2 The cerebral blood vessels in the 600mm diameter area are narrow, highly tortuous, and have a complex network structure. In particular, dense abnormal vascular proliferation has formed at the 500mm location of the lesion, posing significant challenges to neurointervention. Compared to the structure of the 600mm cerebral blood vessels, Figure 3 and Figure 4 The cardiovascular vessels in the brain have a wider diameter and simpler structural complexity and curvature, making them much easier to implement than cerebral vascular interventional therapy.

[0050] Because the inner diameter of the cerebral blood vessel 600 is small, in order for the laser conduit 200 to move smoothly within the cerebral blood vessel 600, the outer diameter of the laser conduit 200 needs to be smaller than the inner diameter of the cerebral blood vessel 600, thus controlling D≤500um; while for capillaries in the cerebral blood vessel 600 with an inner diameter of less than 10um, they generally do not cause major clinical problems, and the smaller the fiber core 210 is, the greater the difficulty of the processing technology and the more difficult it is to achieve mass production. Therefore, taking into account both practical use and processing technology, this application controls D≥10um.

[0051] In this embodiment, the fiber core 210 is made of silicone rubber. Silicone rubber has excellent laser transmission capabilities, ensuring the laser transmission effect, and also has good high-temperature resistance, maintaining good elasticity and flexibility even at high temperatures, allowing the fiber core 210 to move flexibly within the tortuous cerebral blood vessels 600. To enable the fiber core 210 to also have imaging capabilities, allowing it to be visualized under digital subtraction angiography (DSA) or other X-ray imaging devices, rare earth metals are also added to the silicone rubber. In this embodiment, the preferred rare earth metals are one or more of yttrium, neodymium, erbium, and ytterbium. Yttrium, neodymium, erbium, and ytterbium are inexpensive and readily available, reducing the material cost and production difficulty of the fiber core 210.

[0052] like Figure 6 and Figure 7As shown, the catheter body includes, from the inside out, a sheath 220, a protective layer 230, and a lubricating layer 250. Preferably, the sheath 220 covers the fiber core 210, the protective layer 230 is disposed outside the sheath 220, and the lubricating layer 250 is disposed outside the protective layer 230.

[0053] The cladding 220 is made of a gel polymer, which can conduct laser light without being transparent, and also has heat insulation properties and low heat consumption, thereby reducing laser loss and leakage during transmission. At the same time, the gel polymer has good elasticity and flexibility, allowing the cladding 220 to move flexibly within the tortuous cerebral blood vessels 600, ensuring the laser transmission effect without causing damage to the cerebral blood vessels 600.

[0054] The refractive index of the laser in silicone rubber is greater than that in the gel polymer, that is, the refractive index of the laser in the core 210 is greater than that in the cladding 220, so that the laser undergoes total internal reflection between the core 210 and the cladding 220, reducing transmission loss, ensuring the light guide of the laser, and thus ensuring the treatment effect.

[0055] The protective layer 230 protects the cladding 220 and the fiber core 210 to prevent them from being damaged.

[0056] The protective layer 230 and the end 240 are treated with a hydrophilic coating of polytetrafluoroethylene (PTFE), perfluoroethylene propylene copolymer (FEP) or other fluoropolymers to form a lubricating layer 250, which allows the optical fiber to move flexibly in the blood vessel without damaging the structure of the blood vessel itself, ensuring that the optical fiber has excellent biocompatibility.

[0057] Of course, in other embodiments, instead of providing a separate lubrication layer 250 outside the protective layer 230, the protective layer 230 itself may be treated to give it lubricating properties.

[0058] The structural design of optical fibers and the synergistic combination of materials can significantly improve the elasticity, toughness and flexibility of optical fibers, ensuring that optical fibers have excellent mechanical properties and biocompatibility. In addition, the laser conduit 200 is smooth and without sharp edges, so it will not cause any damage to the cerebral blood vessels 600 during treatment.

[0059] Cerebrovascular diseases mainly include hemorrhagic cerebrovascular diseases and ischemic cerebrovascular diseases. Hemorrhagic cerebrovascular diseases include arteriovenous aneurysms, arteriovenous fistulas, arteriovenous malformations, etc., while ischemic cerebrovascular diseases include ischemic stroke, vascular occlusion, vascular stenosis, etc.

[0060] The system described in this application, when used to treat ischemic cerebrovascular disease, utilizes laser to ablate 500 lesions in the cerebral vascular tissue, thereby restoring blood flow to normal levels. For example... Figure 9 As shown, the specific steps are as follows:

[0061] Step S11: The laser catheter 200 is inserted into a peripheral blood vessel (femoral vein or radial vein);

[0062] Step S21: The imaging device guides the laser catheter 200 to move towards the lesion tissue 500;

[0063] Step S31: The imaging device confirms that the laser catheter tip 240 has reached the lesion tissue at position 500;

[0064] Step S41: The host 100 controls the laser output and starts laser treatment to ablate and decompose the lesion tissue at 500 locations;

[0065] Step S51: After the imaging device confirms that the treatment effect has been achieved, the laser output is stopped and the laser catheter 200 is removed.

[0066] In step S41 above, the wavelength of the laser is 800-1500 nm.

[0067] The system described in this application is used to treat hemorrhagic cerebrovascular diseases. It utilizes a combination of local laser irradiation and photochemical agent injection to cut off the blood supply to 500 points in the lesion tissue, achieving an embolization or "clamping" effect, preventing blood flow from passing through these 500 lesion tissue points. Figure 10 As shown, the specific steps are as follows:

[0068] Step S12: The laser catheter 200 is inserted through a peripheral blood vessel (femoral vein or radial vein);

[0069] Step S22: The imaging device guides the laser catheter 200 to move towards the lesion tissue 500;

[0070] Step S32: Inject photochemical reagents into cerebral blood vessels 600 using a microinjection pump;

[0071] Step S42: The imaging device confirms that the laser catheter tip 240 has reached the lesion tissue at position 500;

[0072] Step S52: The host 100 controls the laser output and starts laser treatment so that the photochemical agent is thermally coagulated at 500 on the lesion tissue;

[0073] Step S62: After the imaging device confirms that the treatment effect has been achieved, the laser output is stopped and the laser catheter 200 is removed.

[0074] In step S52 above, the laser wavelength is selected to be 500–1100 nm, and the intensity is 0.1 W–30 W. Different hemorrhagic cerebrovascular diseases require different photochemical agents and appropriate laser wavelengths and intensities. For example, for hemangiomas, a possible combination of photochemical agent and corresponding laser wavelength is rose benzene (Rose Bengal) corresponding to a 532 nm green laser, or a hematoporphyrin derivative corresponding to a helium-neon laser around 630 nm.

[0075] In the above preparation steps, the order of steps S22 and S32 is not fixed. They can be performed simultaneously, or steps S22 can be performed first and then steps S32, or steps S32 can be performed first and then steps S22, as long as there is an appropriate amount of photochemical agent at 500 points of the lesion tissue when laser treatment begins.

[0076] In this embodiment, the system treats cerebrovascular diseases by delivering a laser catheter 200 to the lesion tissue 500 via a blood vessel. The laser output from the laser catheter 200 interacts with the lesion tissue 500, thereby treating the lesion tissue and restoring normal blood perfusion. For ischemic cerebrovascular diseases and vascular stenosis, the high energy of the laser is used to ablate and decompose the obstructive substances within the blood vessel, thereby restoring normal blood vessel diameter and blood perfusion. For hemorrhagic cerebrovascular diseases, local laser irradiation combined with the injection of photochemical agents produces a photochemical reaction, resulting in local blood coagulation and blockage, thereby cutting off the blood supply to the lesion tissue 500, achieving an effect similar to coil embolization. Simultaneously, the wavelength of the laser used is insensitive to the blood vessel wall tissue; that is, the energy of the laser will not cause any damage to the blood vessel wall, and therefore will not destroy the structure of the cerebral blood vessels 600.

[0077] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0078] The embodiments described above are merely illustrative of several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent application. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the scope of protection of this application. Therefore, the patent protection scope of this application should be determined by the appended claims.

Claims

1. A treatment system for cerebrovascular diseases, characterized in that, The device includes an imaging device and a laser treatment device. The laser treatment device includes a main unit and a laser conduit for treating cerebrovascular diseases. The laser conduit is connected to the main unit. The imaging device monitors the patient's brain condition in real time and guides the laser conduit to move in the cerebral blood vessels toward the cerebrovascular lesion. The main unit controls the output of the laser when the end of the laser conduit reaches the cerebrovascular lesion. The laser conduit includes a conduit body and a fiber core. The fiber core is used for laser transmission and can be visualized. The conduit body is wrapped around the fiber core. The outer diameter of the conduit body is D, and D needs to satisfy 10um≤D≤500um. The catheter body includes a cladding that covers the fiber core, the refractive index of the fiber core being greater than the refractive index of the cladding; the cladding is a gel polymer cladding. The fiber core is a silicone rubber fiber core, and the silicone rubber contains rare earth metals; The rare earth metals include one or more of yttrium, neodymium, erbium, and ytterbium; The imaging device displays the condition of the cerebral blood vessels and guides the laser catheter to move within the cerebral blood vessels; when the tip of the laser catheter reaches the cerebral vascular lesion tissue, the host controls the output of the laser to irradiate the cerebral vascular lesion tissue. The host computer controls the output of the laser to irradiate the cerebrovascular lesion tissue, including: controlling the wavelength of the output laser through the host computer so that the cerebrovascular lesion tissue is ablated under the irradiation of the laser. Alternatively, a photochemical reagent can be injected into the cerebrovascular lesion tissue, and the wavelength of the output laser can be controlled by the host machine. The laser irradiation causes the photochemical reagent to thermally coagulate and embolize the cerebrovascular lesion tissue.

2. The cerebrovascular disease treatment system according to claim 1, characterized in that, The catheter body also includes a protective layer, which is disposed outside the sheath to protect the sheath and the fiber core.

3. The cerebrovascular disease treatment system according to claim 1, characterized in that, The catheter body also includes a lubricating layer, which is disposed outside the sheath.

4. The cerebrovascular disease treatment system according to claim 1, characterized in that, The laser transmitted in the fiber core has a wavelength of 500-1100nm and an intensity of 0.1W-30W. The laser can thermally coagulate photochemical agents in cerebral blood vessels at the lesion site of cerebral blood vessels.

5. The cerebrovascular disease treatment system according to claim 1, characterized in that, The wavelength of the laser transmitted in the fiber core is 800-1500nm, and the laser can ablate cerebrovascular lesions.

Images